COMMUNIQUÉS West-GlobeNewswire

-
Therini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases
29/04/2025 - 16:00 -
Rakovina Therapeutics Showcases Preclinical Results of Novel AI-Discovered Cancer Therapies at AACR 2025
29/04/2025 - 16:00 -
Kriya Announces Thirteen Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2025
29/04/2025 - 16:00 -
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
29/04/2025 - 16:00 -
Axiom Medical Marks 25 Years of Advancing Workplace Safety and Health at Annual Client Summit
29/04/2025 - 16:00 -
AscellaHealth Honored as Silver Stevie® Award Winner in 2025 American Business Awards®
29/04/2025 - 16:03 -
FOXO TECHNOLOGIES INC. ANNOUNCES COMPLETION OF REVERSE STOCK SPLIT
29/04/2025 - 16:05 -
Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025
29/04/2025 - 16:39 -
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
29/04/2025 - 17:00 -
remMD Launches Glow Guide: A Smart Mobility Accessory Designed to Support Safer, Smarter Movement for Aging Adults
29/04/2025 - 17:00 -
Semen & Cum Pills - Best Volume Pills of 2025 (Supplements for Bigger Loads) - By Semanax
29/04/2025 - 12:16 -
Regeneron Reports First Quarter 2025 Financial and Operating Results
29/04/2025 - 12:30 -
Le TAR-200 en monothérapie de Johnson & Johnson permet d’atteindre un taux élevé de survie sans maladie de plus de 80 pour cent chez les patients atteints de CVNIM à haut risque papillaire et non sensibles au BCG
29/04/2025 - 12:35 -
Ostarine Mk-2866 SARMs: Ostarine Cycle, Osta 2866 Benefits, Ostarine PCT, Ostarine Mk-2866 Dosage, Osta 2866 Side Effects, What Is Ostarine, Buy, Before and After By CrazyBulk
29/04/2025 - 12:45 -
EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy
29/04/2025 - 13:00 -
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
29/04/2025 - 13:00 -
Skye Bioscience to Participate in May Investment and Medical Conferences
29/04/2025 - 13:00 -
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
29/04/2025 - 13:00 -
Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences
29/04/2025 - 13:00
Pages